Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Allegations and Financial Performance - The lawsuit claims that Synopsys misled investors by stating that customers relied on its IP to minimize integration risk and that the company was experiencing strength in Europe and South Korea. However, it is alleged that customers required more customization for IP components, negatively impacting the economics of the Design IP business and threatening its business model [5]. - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, which is a 43% year-over-year decline. The company indicated that increased customization demands from customers were prolonging processes and requiring more resources [6]. Stock Market Reaction - Following the release of disappointing Q3 2025 financial results, Synopsys's stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, marking a nearly 36% decline [6].

Core Viewpoint - The CarMax class action lawsuit alleges that the company and its executives misrepresented growth prospects, leading to significant investor losses during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Cap v. CarMax, Inc., and it allows investors who purchased CarMax securities between June 20, 2025, and September 24, 2025, to seek lead plaintiff status by January 2, 2026 [1][5]. - The lawsuit claims that CarMax's growth in fiscal year 2026 was overstated and was primarily driven by temporary factors related to customer behavior influenced by tariff speculation [3][4]. Group 2: Financial Performance - On September 25, 2025, CarMax reported a 5.4% decrease in retail unit sales and a 6.3% decrease in comparable store unit sales for the second quarter of fiscal year 2026 [4]. - The company's net earnings per diluted share fell to $0.64 from $0.85 a year ago, which contributed to a 20% drop in share price following the announcement [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is leading the class action, known for its significant recoveries in securities fraud cases, having secured over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to the poor launch of its Inspire V device for obstructive sleep apnea treatment [1][3]. Company Overview - Inspire Medical develops and manufactures an implantable medical device called "Inspire" for treating obstructive sleep apnea, with its latest version being Inspire V, which includes an implanted sensor and neurostimulator [2]. Allegations of the Lawsuit - The lawsuit claims that during the class period, Inspire Medical and its executives made false or misleading statements regarding the launch of Inspire V, asserting that demand was strong when, in fact, there was significant surplus inventory and reluctance from providers to adopt the new treatment [3]. - On August 4, 2025, Inspire Medical disclosed that the launch of Inspire V was facing an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at implanting centers, which hindered the ability to bill for procedures [4]. - Following the negative news, Inspire Medical reduced its 2025 earnings guidance by over 80%, leading to a more than 32% decline in the company's stock price [4]. Legal Process - Investors who purchased Inspire Medical common stock during the class period have until January 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [1][5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone, and is recognized for obtaining significant recoveries in securities class action cases [6].

Core Insights - Kirby McInerney LLP is investigating potential claims against Trex Company, Inc. regarding possible violations of federal securities laws or unlawful business practices [1][3] Financial Performance - Trex reported disappointing Q3 2025 financial results with net sales of $285 million, which was 5% below the mid-point of its guidance and a sequential decline of approximately 26% [4] - The company experienced a 12% decline in net income per share for the nine months ended September 30, 2025, compared to the prior year [4] - Trex revised its FY 2025 sales growth guidance down to roughly 0% compared to 2024, indicating a "muted" fourth quarter due to expected inventory reductions by pro channel partners [4] Market Reaction - Following the announcement of the disappointing results, Trex's share price fell by $14.61, or about 31.07%, from $47.04 on November 4, 2025, to close at $32.43 on November 5, 2025 [4]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for allegedly defrauding investors regarding the launch of their new sleep apnea device, Inspire V, by making misleading statements and failing to disclose adverse facts [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated on behalf of the City of Pontiac Reestablished General Employees' Retirement System against Inspire Medical and three senior executives, including CEO Timothy Herbert, CFO Richard Buchholz, and Chief Strategy and Growth Officer Carlton Weatherby [1][2]. - The class period for the lawsuit spans from August 6, 2024, to August 4, 2025, during which the alleged misrepresentations occurred [2]. - The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, focusing on misleading statements about the market demand and launch readiness of Inspire V [4]. Group 2: Product Information - Inspire Medical develops an implantable device called Inspire to treat obstructive sleep apnea, with the latest version, Inspire V, designed to enhance respiration during sleep through an implanted sensor and neurostimulator [3]. Group 3: Impact of the Allegations - On August 4, 2025, Inspire Medical disclosed that the launch of Inspire V was facing delays due to incomplete training and onboarding at treatment centers, which led to poor demand and excess inventory [5]. - Following this revelation, the company's stock price plummeted over 32%, from $129.95 to $87.91 per share, resulting in a loss of $1.2 billion in market capitalization in one day [6]. - From a high of $216.71 per share on September 23, 2024, the stock price dropped nearly 60%, erasing billions from the company's market capitalization [7].

Core Points - Rosen Law Firm is reminding purchasers of Fly-E Group, Inc. securities about the lead plaintiff deadline for a class action lawsuit, which is set for November 10, 2025 [1][3] - Investors who purchased Fly-E securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The lawsuit alleges that Fly-E Group provided misleading statements regarding the safety of its lithium batteries, which negatively impacted its electric vehicle sales revenue [5] - Despite optimistic long-term projections, Fly-E's sales continued to decline while operating expenses increased, leading to a failure in meeting revenue forecasts [5] Legal Process - A class action lawsuit has already been filed, and interested investors can join by contacting Rosen Law Firm [3][6] - Investors are advised to select qualified legal counsel with a successful track record in securities class actions [4]

Core Points - Rosen Law Firm is reminding purchasers of Fortinet, Inc. common stock from November 8, 2024, to August 6, 2025, about the lead plaintiff deadline on November 21, 2025 [1] - Investors who purchased Fortinet stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Class Action Details - A class action lawsuit has been filed against Fortinet, and interested parties can join by submitting a form or contacting the law firm [3][7] - The lawsuit alleges that Fortinet made materially false and misleading statements regarding the business impact of a "record" round of FortiGate unit upgrades, claiming it would generate $400 million to $450 million in product revenue in 2025 and 2026 [5][6] Allegations Against Fortinet - The lawsuit claims that Fortinet misrepresented the potential of the refresh cycle, which consisted of older products that were a "small percentage" of the company's business [6] - It is alleged that Fortinet concealed the true number of FortiGate firewalls eligible for upgrades and misled investors about the momentum of the refresh cycle, which was pushed through rapidly in a short time frame [6]

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom, Inc." or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom, Inc. investors who were adversely affected by alleged securities fraud between July 26, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/dexcom-inc-lawsuit-s ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product malfunctions and inadequate responses to these issues [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter's Novum LVP product suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths linked to these defects, yet their remedial measures were deemed inadequate [2]. Group 2: Implications for Baxter - Due to the ongoing issues with the Novum LVP, there is a heightened risk that customers may be instructed to take these devices out of service, potentially halting all new sales [2]. - Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs have been characterized as materially false and misleading [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4].

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...